Rights and permissions
About this article
Cite this article
PEG IFN-α-2a + ribavirin confers significant benefit for little extra cost. Pharmacoecon. Outcomes News 479, 7 (2005). https://doi.org/10.2165/00151234-200504790-00021
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200504790-00021